Age: 56.0
Sex: F
Vaccine: COVID19
Symptoms: Ageusia, Anosmia, COVID-19, Eye pruritus, Hypersensitivity
Clinical narrative: Red/itchy eyes; felt like I had a cold; Covid19; Congestion; Inflamed nose; Allergies; Sinus infection; Migraine; Injection site soreness; lost taste; lost smell; This spontaneous case was reported by a consumer and describes the occurrence of HYPERSENSITIVITY (Allergies), SINUSITIS (Sinus infection), NASAL INFLAMMATION (Inflamed nose), MIGRAINE (Migraine) and NASAL CONGESTION (Congestion) in a 56-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch nos. 038A21A and 006M20A) for COVID-19 vaccination. The occurrence of additional non-serious events is detailed below.     The patient's past medical history included Shortness of breath (Shortness of breath ongoing like asthma.) since an unknown date and Chemotherapy (Patient had Chemo 6 years ago.). Previously administered products included for an unreported indication: Flu shot (Hot red arm swollen.) in 2009. Past adverse reactions to the above products included Swollen arm with Flu shot. Concurrent medical conditions included Reaction to vaccine preservatives (Determined to have allergy to thimerasol.), Hypersensitivity reaction (NOS), Hay fever and Breast cancer (improved - no evidence of disease after chemo in 2015/16 since) since 07-Nov-2015. Concomitant products included VITAMIN D NOS, VITAMIN E NOS, VITAMIN B NOS and VITAMIN C [ASCORBIC ACID] for an unknown indication.   On 11-Feb-2021 at 4:45 PM, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 11-Mar-2021 at 4:30 PM, received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) dosage was changed to 1 dosage form. On 12-Mar-2021, the patient experienced MIGRAINE (Migraine) and INJECTION SITE PAIN (Injection site soreness). On 06-Apr-2021, the patient experienced HYPERSENSITIVITY (Allergies) and SINUSITIS (Sinus infection). On 07-Apr-2021, the patient experienced NASAL INFLAMMATION (Inflamed nose). 07-Apr-2021, the patient experienced NASAL CONGESTION (Congestion). On 08-Apr-2021, the patient experienced COVID-19 (Covid19). On an unknown date, the patient experienced EYE PRURITUS (Red/itchy eyes), NASOPHARYNGITIS (felt like I had a cold), AGEUSIA (lost taste) and ANOSMIA (lost smell). The patient was treated with FLUTICASONE PROPIONATE (FLONASE ALLERGY RELIEF) for Allergy, at a dose of 1 dosage form and AZITHROMYCIN (Z-PAK) on 07-Apr-2021 for Sinus infection, at a dose of 1 dosage form. On 12-Mar-2021, MIGRAINE (Migraine) and INJECTION SITE PAIN (Injection site soreness) had resolved. On 12-Apr-2021, COVID-19 (Covid19), AGEUSIA (lost taste) and ANOSMIA (lost smell) had resolved. At the time of the report, HYPERSENSITIVITY (Allergies), SINUSITIS (Sinus infection), NASAL INFLAMMATION (Inflamed nose), NASAL CONGESTION (Congestion), EYE PRURITUS (Red/itchy eyes) and NASOPHARYNGITIS (felt like I had a cold) outcome was unknown.      DIAGNOSTIC RESULTS (normal ranges are provided in parenthesis if available): On 07-Apr-2021, SARS-CoV-2 test: negative (Negative) went again to get a Covid 19 test, after the second dose. Rapid Test was negative. On 08-Apr-2021, SARS-CoV-2 test: positive (Positive) the overnight test on 4/8 was positive..         Patient had Sinus washes as one of her treatment medication for sinus.  Action taken with mRNA-1273 in response to the events was Not Applicable   This case was linked to MOD-2021-073384 (Patient Link).   Most recent FOLLOW-UP information incorporated above includes: On 20-Jun-2021: Follow-up document contains Patient Height & Weight, events like COVID-19 details and event outcome.